Hormones, herbal preparations and nutriceuticals for a better life after the menopause: Part I

Climacteric

Volumn 18, Issue 3, 2015, Pages 358-363

  Comhaire, F H ^a   Depypere, H T ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Herbal preparations; Hormones; Menopause; Nutriceuticals

Indexed keywords

BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTRADIOL; ESTRIOL; ESTROGEN; HERBACEOUS AGENT; HORMONE; NUTRACEUTICAL; PRASTERONE; RETINOL; VITAMIN D; PHYTOESTROGEN; PLANT MEDICINAL PRODUCT;

ARTICLE; ATRIAL FIBRILLATION; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLELITHIASIS; DIET SUPPLEMENTATION; ESTROGEN THERAPY; HEART INFARCTION; HUMAN; LONG TERM CARE; MENOPAUSAL SYNDROME; MENOPAUSE; MINERAL SUPPLEMENTATION; OUTCOME ASSESSMENT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS; STRESS INCONTINENCE; THROMBOEMBOLISM; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION; WELLBEING; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DRUG EFFECTS; DYSPAREUNIA; FEMALE; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VAGINA;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DYSPAREUNIA; ESTRADIOL; ESTRIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PHYTOESTROGENS; PLANT PREPARATIONS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VAGINA;

EID: 84929325920     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.985645     Document Type: Article

References (94)

1. http://statbel.fgov. be/nl/statistieken/cijfers/bevolking/sterfte-leven/tafels/
2. Dibonaventura MD, Chandran A, Hsu MA, Bushmakin A. Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom. Int J Womens Health 2012;5:261-9
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Pricipal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
4. Burger HG, Maclennan AH, Huang KE, Castelo-Branco C. Evidence-based assessment of the impact of the WHI on women's health. Climacteric 2012;15:381-7
5. Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241-9
6. Sood R, Faubion SS, Kuhle CL, Thiele JM, Shuster L T. Prescribing menopausal hormone therapy: an evidence-base approach. Int J Womens Health 2014;6:47-57
7. Comhaire FH, Depypere HT. Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part II. Climacteric 2015;18:364-71
8. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47
9. Conard J. Modifications of the hemostatic balance during estrogen treatments: menopause and its treatment. Therapie 1999;54:363-7
10. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
11. Palacios S, Christiansen C, Sànchez Borrego R, et al. Recommendations on the management of fragility fracture risk in women younger than 70 years. Gynecol Endocrinol 2012;28:770-86
12. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012;7, CD002143
13. Gambacciani M. HRT misuse and the osteoporosis epidemic. Climacteric 2012;15:10-11
14. Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2014;383:146-55
15. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45
16. ®. Osteoporos Int 2013;24:2561-9
17. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96
18. Pazianas M, Epstein S, Zaidi M. Evaluating the antifracture efficacy of bisphosphonates. Rev Recent Clin Trials 2009;4:122-30
19. Cummings SR, San Martin J, McClung M, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;36:756-65
20. Comhaire F, Vandeweghe M, Vermeulen A. Vascular incidents and oral contraceptives, arterial versus venous thromboembolism: a statistical study. Contraception 1971;3:301-5
21. ESC/EAS. Guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-818
22. Kawecka-Jaszcz K, Czarnecka D, Olszanecka A, et al. The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. J Hum Hypertens 2002;16:509-16
23. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6-12
24. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
25. Chu MC, Cushman M, Solomon R, Lobo RA. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. Am J Obstet Gynecol 2008;199:526.e1-7
26. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-25
27. Stephenson K, Neuenschwander PF, Kurdowska AK. The effects of compounded biological transdermal hormone replacement therapy on hemostatic, inflammatory, inmune factors; cardiovascular biomarkers; quality-of-life measures, and health outcomes in perimenopausal and postmenopausal women. Int J Pharm Comp 2013;17:74-85
28. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14
29. Salpeter SR, Cheng J, Thabane L, Buckley N, Salpeter E. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;122:1016-22
30. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41
31. Schierbeck L, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409
32. Bretler DM, Hansen PR, Lindhardsen J, et al. Hormone replacement therapy and risk of new-onset atrial fibrillation after myocardial infarction - a nationwide cohort study. PLoSOne 2012;7:e51580
33. Rockman CB, Maldonado TS, Jacobowitz GR, et al. Hormone replacement therapy is associated with a decreased prevalence of peripheral arterial disease in postmenopausal women. Ann Vasc Surg 2012;26:411-18
34. Ruszkowska B, Gadomska G, Bielis L, et al. Risk of venous thromboembolic disease in postmenopausal women taking oral or transdermal hormone replacement therapy. J Zheijang Univ Sci B 2011;12:12-17
35. Wakatsuki A, Ikenoue N, Shinohara K, et al. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women. Arteriosclerosis 2003;23:1948-9
36. Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005;293:935-48
37. Robinson D, Cardozo L. Estrogens and the lower urinary tract. Neurourol Urodyn 2011;30:754-7
38. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; (4): CD001500
39. Grady D, Brown J, Vittinghoff E, Applegate W, Varner E, Snyder T, for the HERS research group. Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet Gynecol 2001;97:116-20
40. Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012;10:CD 001405
41. Lüthje P, Brauner H, Ramos NL, et al. Estrogen supports urothelial defense mechanisms. Sci Transl Med 2013;5:190r a80
42. Lammerink EA, de Bock GH, Schröder CP, Mourits MJ. The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas 2012;73:265-8
43. Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 2013;17:526-35
44. Chen WY. Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions. Endocrinol Metab Clin North Am 2011;40:509-18
45. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005;23:1370-8
46. Amadou A, Hainaut P, Romieu I. Role of obesity in the risk of breast cancer: lessons from anthropometry. J Oncol 2013;2013:906495
47. Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260-8
48. Lidegaard O, Løkkegaard E, Helms A; Danish Sex Hormone Register Study. Hormone therapy and breast cancer. 2011 www.slideserve.com/.../Danish-sex-Hormone-Register-Study-DaHoRS
49. Shoupe D. Individualizing hormone therapy to minimize risk: accurate assessment of risks and benefits. Womens Health 2011;7:475-85
50. Opatrny L, Dell'Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008;115:169-75
51. Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices. Contraception 2007;75(6 Suppl):S60-9
52. Myytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carriers a risk as well. Int J Cancer 2010;15:483-9
53. Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011;83:211-17
54. Wong A W, Chan SS, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol 2013;121:943-50
55. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012;8:CD 000402
56. Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med 1999;8:1155-66
57. Wu AH, Siegmund KD, Long TI, et al. Hormone therapy, DNA methylation and colon cancer. Carcinogenesis 2010;31:1060-7
58. Slatore CG, Chien JW, Au dh, et al. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 2010;28:1540-6
59. Chen KY, Hsiao CF, Chang GC, et al. Hormone replacement therapy and lung cancer risk in Chinese. Cancer 2007;110:1768-75
60. Ayeni O, Robinson A. Hormone replacement therapy and the outcomes for women with non-small-cell lung cancer: can an association be confirmed? Curr Oncol 2009;16:21-5
61. Chen KY, Hsiao CF, Chang GC, et al. EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women. Carcinogenesis 2013;34:612-19
62. Hart AR, Luben R, Welch A, Bingham S, Khaw KT. Hormone replacement therapy and symptomatic gallstones - a prospective population study in the EPIC-Norfolk cohort. Digestion 2008;77:4-9
63. Uhler ML, Marks JW, Voigt BJ, Judd HL. Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women. J Clin Endocriol Metab 1998;83:410-14
64. Gambacciani M, Cappagli B, Ciaponi M, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;59:2-6
65. Tuppurainen M, Härmä K, Komulainen M, et al. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up. Maturitas 2010;66:426-30
66. Hodis HN, Mack WJ. Coronary heart disease and hormone replacement therapy after the menopause. Climacteric 2009;12(Suppl 1):71-5
67. Kika G, Izumi S, Mori A, et al. Beneficial aspect of oral estriol as hormone replacement therapy: consideration on bone and lipid metabolism. Tokai J Exp Clin Med 2009;34:92-8
68. Sites CK, Brochu M, Tchernof A, Poehlman ET. Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women. Metabolism 2001;50:835-40
69. Sörensen MB, Rosenfalck AM, Höjgaard L, Ottensen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res 2001;9:622-6
70. Ferrara A, Karter AJ, Ackerson LM, et al. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: The Northern California Kaiser Permanente Diabetes Registry. Diabetes Care 2001;24:1144-50
71. Welton AJ, Vickers MR, Kim J, et al.; WISDOM team. Health related quality of life after combined hormone replacement therapy: randomized controlled trial. BMJ 2008;337:a1190
72. Gast MJ, Freedman MA, Vieweg AJ, et al. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 2009;16:247-56
73. Lethaby A, Hogervorst E, Richards M, et al. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD 003122
74. Ross LA, Alder EM, Cawood EH, et al. Psychological effects of hormone replacement therapy: a comparison of tibolone and sequential estrogen therapy. J Psychosom Obstet Gynaecol 1999;20;88-96
75. Patacchioli FR, Simeoni S, Monnazzi P, Pace M, Capri O, Perrone G. Menopause, mild psychological stress and salivary cortisol: influence of long-term hormone replacement therapy (HRT). Maturitas 2006;55:150-5
76. Katz-Bearnot S. Menopause, depression, and loss of sexual desire: a psychodynamic contribution. J Am Acad Psychoanal Dyn Psychiatry 2010;38:99-116
77. Polo-Kantola P, Erkkola R. Sleep and the menopause. J Br Menopause Soc 2004;10:145-50
78. Magliano M. Menopausal arthralgia: Fact or fiction. Maturitas 2010;67:29-33
79. Sator PG, Sator MO, Schmidt JB, et al. A prospective, randomized, double-blind, placebo-controlled study on the influence of hormone replacement therapy on skin aging in postmenopausal women. Climacteric 2007;10:320-34
80. Stevenson S, Thornton J. Effect of estrogens on skin aging and the potential role of SERMs. Clin Interv Aging 2007;2:283-97
81. Guashino S; Grimaldi E, Satore A, et al. Visual function in menopause: the role of hormone replacement therapy. Menopause 2003;10:53-7
82. Noreen F, Roosli M, Gaj P, et al. Modulation of age- and cancer associated DNA methylation change in healthy colon by aspirin and lifestyle. J Natl Cancer Inst 2014;106(7). Pii: dju 161
83. Blumenfeld Z, Boulman N, Leiba R, et al. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scand J Lab Invest 2007;67:257-63
84. Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 1996;81:3147-51
85. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulphate, and aging: contribution of the DHEAage Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279-84
86. Percheron G, Hogrel JY, Denot-Ledunois S, et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-yearold individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med 2003;163:720-7
87. Genazzani AR, Stomati M, Valentino V, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric 2011;14:661-8
88. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med 2009;6:2579-90
89. López-Marure R, Contreras PG, Dillon JS. Effects of dehydroepiandrosterone on proliferation, migration, and death of breast cancer cells. Eur J Pharmacol 2011;660:268-74
90. Gomez-Santos C, Hernandez-Morante JJ, Tébar FJ, Granero E, Garaulet M. Differential effect of dehydroepiandrosteronesulphate on metabolic syndrome features in pre- and postmenopausal obese women. Clin Endocinol (Oxf) 2012;77:548-54
91. Weiss EP, Villareal DT, Fontana L, Han DH, Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging 2011;3:533-42
92. Savineau JP, Marthan R, Dumas de la Roque E. Role of DHEA in cardiovascular diseases. Biochem Pharmacol 2013;85:718-26
93. Weiss EP, Villareal DT, Ehsani AA, Fpntana L, Holloszy JO. Dehydroepiandrosterone replacement therapy in older adults improves indices of arterial stiffness. Aging Cell 2012;11:876-84
94. Goel RM, Cappola AR. Dehydroepiandrosterone sulfate and postmenopausal women. Curr Opin Endrocrinol Diabetes Obes 2011;18:171